Standard treatment for accelerated or blast phase myeloproliferative neoplasms (MPNs) consists of hypomethylating agents (HMAs) or intensive induction chemotherapy and transplant. However, newer studies have suggested that accelerated or blast phase MPNs, such as acute myeloid leukemia (AML), can be treated with molecularly driven targeted therapies.
Srdan Verstovsek, MD, explained the current treatment paradigm for patients with accelerated or blast phase MPNs as well as emerging therapies in this setting in a presentation during the Texas Virtual MPN Workshop.1
Current Paradigm and Unmet Needs
Verstovsek, professor in the Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explained that there are 3 phases of MPNs: chronic, accelerated, and blast (or post-MPN AML), which are determined by the percentage of blasts in the peripheral blood or bone marrow. These phases affect each type of MPN: essential thrombocytopenia (ET), polycythemia vera (PV), and myelofibrosis. In the chronic phase there are less than 10% blasts found in the peripheral blood or bone marrow, and in the blast phase theres 20% or more.
Blast-phase MPNs are associated with a very poor prognosis. It unfortunately has not changed very much over many yearswe have a lot to do, Verstovsek said.
Additionally, those with blast-phase MPNs show limited responses to conventional treatments for AML. In an analysis of 91 patients who developed post-MPN AML, patients who were treated with conventional treatments did not show significant survival differences compared with those who were not treated. The median survival among patients who received induction chemotherapy was 3.9 months compared with 2.1 months for those who did not receive any chemotherapy.2
Stem cell transplant, however, does have a more significant impact on survival following induction chemotherapy. Only patients that achieve complete response [CR] and go for transplant do well, Verstovsek said.
One analysis showed that the rate of overall survival (OS) among patients who did not achieve a CR from induction chemotherapy prior to transplant was 22% compared with 69% among patients who did have a CR (P = .008).3 He said that overall, the chance of achieving a CR with induction chemotherapy is approximately 35% to 40%.4
An alternative to induction chemotherapy is azacitidine, which has shown comparable survival rates to chemotherapy in post-MPN AML. In a study of 73 patients with post-MPN AML, no statistically significant difference was observed in either event-free survival or OS between those treated with chemotherapy or azacitidine. The event-free survival was 4.2 months with induction chemotherapy and 5.8 months with azacitidine (P = .4443) and the median OS was 8.3 and 7.9 months, respectively (P = .9842). Response rates were also similar at 58.8% with chemotherapy and 54.6% with azacitidine.5
The patients that transform from chronic phase MPN to blastic phase MPN actually pass through accelerated phase MPN. That is rather a rule. Its extraordinarily rare that overnight the patient comes from chronic phase to blastic phase, usually you see blasts coming up, Verstovsek said. That is useful because we dont want to wait for patients to transform. If we can follow patients closely, we would be intervening with hypomethylating agents in the accelerated phase.
Research suggests that patients benefit more from HMAs in the accelerated phase than in the blast phase. A retrospective study of patients with high-risk myelofibrosis in the accelerated or blast phase who were treated with decitabine showed that the OS among patients in the blast phase was 6.9 months, but those in the accelerated phase had a median OS of 9.7 months. Among those who responded to decitabine, the median OS was 10.5 months for those in the blast phase and 11.8 months for those in the accelerated phase.6
As ruxolitinib (Jakafi) is standard of care in treating patients with myelofibrosis, the JAK inhibitor has been investigated in clinical trials in combination with HMAs for the treatment of patients with accelerated and blast phase MPNs. When we talk about transformation to accelerated/blastic phase, we are usually talking about [patients with] myelofibrosis transforming, they are in bad physical shape, they have a very big spleen, very big liver, so there is utility perhaps in giving them ruxolitinib, Verstovsek said.
In a phase 1/2 study of ruxolitinib and decitabine in 29 patients with blast phase MPN, treatment with up to 50 mg of ruxolitinib twice daily and 20 mg/m2 of intravenous decitabine for 5 days on a 4 to 6 week schedule led to a response rate of 45%, which included a CR rate of 7%. The median OS for patients who responded to treatment was 9.4 months compared with 6.2 months in those who did not respond.7
We already know that ruxolitinib is not active in preventing progression. On its own its not active in accelerated or blast phasethats already well known, Verstovsek said.
The National Comprehensive Cancer Network (NCCN) guidelines for MPNs now include that ruxolitinib or fedratinib (Inrebic) can be given close to the start of conditioning treatment for the improvement of splenomegaly or disease-related symptoms.8
Overall, Verstovsek suggested starting with HMAs for 2 to 3 cycles because it canbedelivered in the outpatient setting and is not as toxic as chemotherapy, leading to better quality of life for the patient.
Moving Toward a Molecularly Targeted Approach
New medications are being developed for de novo acute myeloid leukemia, so why not use some of them in the setting of post-MPN AML or even in accelerated phase MPN? Verstovsek suggested.
Mutational analyses have shown a significant difference in the mutation frequency found between de novo AML and accelerated or blast phase MPNs. One mutation that is found more often in accelerated or blast phase MPN is IDH1/2, and agents are already available to target these alterations.
Small studies have already shown promise for this approach of treating patients with IDH1/2-mutant accelerated or blast phase MPNs with an IDH1/2 inhibitor. In a small study of 12 patients with IDH1/2-mutant post-MPN AML treated with IDH1/2 inhibitorbased regimens, 3 of 7 patients treated in the frontline setting had a CR and a median duration of response of 17.5+ months was reported. Two patients treated in the frontline and 3 in the relapsed/refractory setting also had stable disease.1
Targeted agentsis the way of the futureidentifying patients based on genetic profile and targeting those mutations for which we have medications, Verstovsek said.
A study has also considered treatment with venetoclax (Venclexta)based combination regimens. The study included 29 patients treated in the frontline or relapsed/refractory setting. Six of the 14 patients treated in the frontline setting achieved a CR or complete response with incomplete hematologic recovery from treatment with the venetoclax regimen and showed a median duration of response of 6 months. However, there was a high degree of infections and mortality in the first 60 days of treatment.1
Additionally, when comparing the venetoclax regimen to other treatment regimens, no survival benefit was found with the use of venetoclax.
Verstovsek summarized that those with targetable mutations, such as IDH1/2 or FLT3 mutations, should receive these targeted treatments, and those with no targetable mutation should receive HMA-based therapy or intensive chemotherapy, and all patients are recommended to undergo allogeneic stem cell transplant if they achieve a complete response and are eligible for transplant.
1. Verstovsek S. Therapy Strategies for Accelerated and Blastic Phase MPN. Presented at: Texas Virtual MPN Workshop; August 27-28, 2020; Virtual.
2. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977. doi:10.1182/blood-2004-07-2864
3. Alchalby H, Zabelina T, Stubig T, et al; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Bio Blood Marrow Trasplant. 2014;20(2):279-281. doi:10.1016/j.bbmt.2013.10.027
4. Mascarenhas J. A concise update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms. Clin Lymph Myel Leuk. 2016;16(suppl):S124-S129. doi:10.1016/j.clml.2016.02.016
5. Venton G, Courtier F, Charbonnier A, et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2018;93(3):330-338. doi:10.1002/ajh.24973
6. Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015;39(9):950-956. doi:10.1016/j.leukres.2015.06.001
7. Bose P, Verstovsek S, Cortes JE, et al. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020;34(9):2489-2492. doi:10.1038/s41375-020-0778-0
8. NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative neoplasms, version 1.2020. Accessed August 28, 2020. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf
- US FDA Approves Naxitamab for the Treatment of Neuroblastoma - OncoZine - November 29th, 2020
- Coronavirus treatments and vaccines. Here are the latest developments - San Francisco Chronicle - November 29th, 2020
- Dr Apar Kishor Ganti Outlines the Effectiveness of Lurbinectedin and Benefits Over Competition - AJMC.com Managed Markets Network - November 26th, 2020
- Commonly used antibiotic shows promise for combating Zika infections - National Institutes of Health - November 26th, 2020
- A real life Superman celebrates 5 years of survival from one of the deadliest cancers - Newswise - November 26th, 2020
- Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - Salamanca Press - November 26th, 2020
- Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel - AJMC.com Managed Markets Network - November 26th, 2020
- Tetracycline-based Antibiotics Show Promise for Combating Zika Infections - Global Biodefense - November 26th, 2020
- Study Suggests AYAs Treated for AML Have High Risk of Developing Long-Term Complications - Cancer Network - November 26th, 2020
- Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment... - November 26th, 2020
- Study Finds Racial and Ethnic Disparities in Treatment of AL Amyloidosis - DocWire News - November 22nd, 2020
- New Virtual Reality Tool, Domestic Cats are SARS-CoV-2 Carriers, Combination Therapy Advances: COVID-19 Updates - Bio-IT World - November 22nd, 2020
- SEE | Smoking worsens Covid-19 infection in the airways, new study reveals - Health24 - November 22nd, 2020
- Could Cell Therapy Be The Answer To COVID-19? - CBS Boston - November 3rd, 2020
- CA Prop 14 Explained: What To Know Before You Vote Election Day - Los Angeles, CA Patch - November 3rd, 2020
- GMP Cell Banking Services Market Predicted to Accelerate the Growth by 2019-2029 - TechnoWeekly - November 3rd, 2020
- Making Progress Against Relapsed/ Refractory DLBCL Without CAR T - OncLive - November 3rd, 2020
- Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020 - GlobeNewswire - November 3rd, 2020
- Editorial Article: Combating cancer: The incubation technology accelerating CAR-T cell therapy development - SelectScience - October 31st, 2020
- Richters Transformation: When a Slow-Growing Cancer Turns Aggressive - SurvivorNet - October 31st, 2020
- Detroit Pistons, Make-A-Wish put a smile on the face of Commerce Township boy - The Oakland Press - October 31st, 2020
- NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia - Yahoo Finance - October 31st, 2020
- HBS and Harvard's Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from The Chris and Carrie Shumway Foundation to Support... - October 23rd, 2020
- Harnessing regeneration of retinal tissues: An option almost within reach - Ophthalmology Times - October 23rd, 2020
- Fate Therapeutics' and Celyad's CAR therapies in oncology offer potential - pharmaceutical-technology.com - October 23rd, 2020
- World Wide Stem Cell Treatment Centers Provides Exceptional Regenerative Treatment Options To Those in Need - GlobeNewswire - October 16th, 2020
- Proposition 14: Stem cell research bonds City Times - City Times - October 16th, 2020
- BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update - PRNewswire - October 16th, 2020
- How a UCSF team is giving Cronutt the sea lion a second chance with neuroscience - University of California - October 16th, 2020
- Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors - PR Web - October 10th, 2020
- Report of the president: Appointments and promotions | Stanford News - Stanford University News - October 10th, 2020
- UTSW Scientist: 'We Need More Women Thinking Creatively in the Lab and Pushing Science Forward' - dallasinnovates.com - October 10th, 2020
- Here's what is known about Trump's COVID-19 treatment - Science Magazine - October 4th, 2020
- Election Guide: Here's What You Need to Know About Proposition 14 - NBC Bay Area - October 4th, 2020
- ASX up 2.3%, banks and energy outperform - The Sydney Morning Herald - October 4th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies MARKET 2020 |INDUSTRY ANALYSIS, SIZE, SHARE, TRENDS, MARKET DEMAND, GROWTH, OPPORTUNITIES AND... - September 25th, 2020
- Finding The Achilles Heel of A Killer Parasite - Newswise - September 25th, 2020
- SHE Initiative Shines Light on Gender Disparities in Oncology Workforce - Targeted Oncology - September 25th, 2020
- Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in... - September 23rd, 2020
- Advances in the Treatment of Mantle Cell Lymphoma are Greatly Improving the Long-Term Outlook for Patients - Curetoday.com - September 23rd, 2020
- CytoDyn's Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on... - September 23rd, 2020
- Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to... - September 23rd, 2020
- Coronavirus Researchers Discover How COVID-19 May Trigger Fatal Levels of Lung Inflammation - SciTechDaily - September 21st, 2020
- The Holistic Sanctuary Announces Exciting Plans to Expand Over Next 4 Years and Save More Lives - PRNewswire - September 21st, 2020
- Robert E. Windsor, MD, is being recognized by Continental Who's Who - PRNewswire - September 21st, 2020
- City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy - Business Wire - September 21st, 2020
- Emerging immunotherapies in multiple myeloma - The BMJ - September 21st, 2020
- ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed... - September 21st, 2020
- Oakland 24-year-old seeking multiethnic bone marrow donor - The Jewish News of Northern California - September 21st, 2020
- First-Line Treatment With Merck's KEYTRUDA (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients... - September 21st, 2020
- Coronavirus, Charity, and the Trolley Problem - Crooked - September 12th, 2020
- Royal Biologics Announces the Acquisition of FIBRINET - PRNewswire - September 1st, 2020
- Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape - Targeted Oncology - September 1st, 2020
- MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European... - August 28th, 2020
- The Inside Story Of Biotechs Barnum And His Covid Cures - Forbes - August 28th, 2020
- Mustang Bio: Slow, Steady Progress Towards Multiple Gene And CAR-T Therapy Goals - Seeking Alpha - August 25th, 2020
- Study sheds light on why retinal ganglion cells are vulnerable to glaucoma - Jill Lopez - August 19th, 2020
- Coronavirus Thursday update: UMN announces new stem cell treatment - TwinCities.com-Pioneer Press - August 15th, 2020
- Health and Fitness: Hip replacement surgery: getting back to what you love - taosnews - August 14th, 2020
- How MC Hammer And Other Performing Artists Are Sharing Their Love Of Science - Forbes - August 12th, 2020
- Chromosomal Rearrangements Associated with Chemotherapeutic Drug Resistance | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra - August 8th, 2020
- Chinese Govt-Compensated Experts Plead Guilty to Thieving Investigation From an American Childrens Medi ... - 90Xtra - August 7th, 2020
- US government considers ethics of aborted tissue research - Angelus News - August 7th, 2020
- Mesa Discusses Treating Myelofibrosis and Other MPNs - Targeted Oncology - August 7th, 2020
- Startup Accelerator: Volumetric Aims to Be the Tissue Bioprinting Farm of the Future - 3DPrint.com - August 6th, 2020
- Cord blood offers hope for rare diseases and ethnic minorities - The Province - August 6th, 2020
- FDA touts advanced manufacturing to address Covid-19 shortfalls - Endpoints News - August 5th, 2020
- Cancer Research Institute Awards $30.2 Million in Grants and Fellowships to Support Basic and Clinical Research in Immunology and Cancer Immunotherapy... - August 5th, 2020
- RenovaCare Appoints Dr. Lydia M. Evans to Its Board of Directors and Increases Board Membership - GlobeNewswire - August 4th, 2020
- MediVet Biologics Rebrands as Ardent Animal Health - Benzinga - August 3rd, 2020
- Church Point Police Captain dies from COVID-19 complications: 'Go and protect the heavens, my dearest friend' - The Advocate - August 1st, 2020
- BMT survivor study finds significant breast cancer risk in young women who received total body irradiation - The Mix - July 31st, 2020
- Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults - PsychCentral.com - July 29th, 2020
- The surprising recovery with stem cells of 26 COVID-19 patient in Hidalgo - Explica - July 29th, 2020
- Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy - Press Release - Digital Journal - July 29th, 2020
- COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - El Paso Inc. - July 25th, 2020
- 'Self-eating' process of stem cells may be the key to new regenerative therapies - 7thSpace Interactive - July 23rd, 2020
- R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico - PR Web - July 23rd, 2020
- CAR T-Cell Therapy Offers Potential Solution for Relapse in MCL, But With Toxicity Risk - Targeted Oncology - July 22nd, 2020
- Fine-tuning adoptive cell therapy for advanced cancers - Newswise - July 22nd, 2020